Idorsia Past Earnings Performance
Past criteria checks 0/6
Idorsia has been growing earnings at an average annual rate of 6.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 26.5% per year.
Key information
6.1%
Earnings growth rate
12.5%
EPS growth rate
Biotechs Industry Growth | 18.9% |
Revenue growth rate | 26.5% |
Return on equity | n/a |
Net Margin | -399.9% |
Next Earnings Update | 27 Feb 2025 |
Recent past performance updates
Recent updates
Improved Revenues Required Before Idorsia Ltd (VTX:IDIA) Stock's 71% Jump Looks Justified
Dec 19One Idorsia Ltd (VTX:IDIA) Analyst Has Been Cutting Their Forecasts
Nov 06Market Cool On Idorsia Ltd's (VTX:IDIA) Revenues Pushing Shares 33% Lower
Nov 04Take Care Before Jumping Onto Idorsia Ltd (VTX:IDIA) Even Though It's 25% Cheaper
Sep 18Idorsia Ltd (VTX:IDIA) Stock Rockets 26% But Many Are Still Ignoring The Company
May 30Idorsia Ltd (VTX:IDIA) Analysts Are Reducing Their Forecasts For This Year
May 26Idorsia Ltd (VTX:IDIA) Analysts Just Slashed Next Year's Revenue Estimates By 17%
May 01Industry Analysts Just Made A Captivating Upgrade To Their Idorsia Ltd (VTX:IDIA) Revenue Forecasts
Apr 05Need To Know: Analysts Are Much More Bullish On Idorsia Ltd (VTX:IDIA) Revenues
Mar 10Idorsia Ltd (VTX:IDIA) Stock Catapults 38% Though Its Price And Business Still Lag The Industry
Mar 08There's No Escaping Idorsia Ltd's (VTX:IDIA) Muted Revenues Despite A 37% Share Price Rise
Dec 28The Idorsia Ltd (VTX:IDIA) Analysts Have Been Trimming Their Sales Forecasts
Jul 27Idorsia Ltd's (VTX:IDIA) P/S Still Appears To Be Reasonable
Jun 14We Think Idorsia (VTX:IDIA) Has A Fair Chunk Of Debt
Apr 13Revenue & Expenses Breakdown
How Idorsia makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 74 | -296 | 285 | 0 |
30 Jun 24 | 128 | 29 | 286 | 0 |
31 Mar 24 | 141 | -56 | 336 | 0 |
31 Dec 23 | 152 | -298 | 393 | 0 |
30 Sep 23 | 185 | -374 | 451 | 0 |
30 Jun 23 | 126 | -814 | 524 | 0 |
31 Mar 23 | 113 | -843 | 529 | 0 |
31 Dec 22 | 97 | -828 | 507 | 0 |
30 Sep 22 | 48 | -887 | 474 | 0 |
30 Jun 22 | 44 | -810 | 391 | 0 |
31 Mar 22 | 34 | -728 | 302 | 0 |
31 Dec 21 | 35 | -635 | 230 | 0 |
30 Sep 21 | 36 | -520 | 161 | 0 |
30 Jun 21 | 27 | -499 | 131 | 0 |
31 Mar 21 | 74 | -429 | 109 | 0 |
31 Dec 20 | 72 | -445 | 97 | 0 |
30 Sep 20 | 70 | -450 | 81 | 0 |
30 Jun 20 | 69 | -451 | 71 | 0 |
31 Mar 20 | 22 | -507 | 69 | 0 |
31 Dec 19 | 24 | -494 | 65 | 0 |
30 Sep 19 | 61 | -460 | 62 | 0 |
30 Jun 19 | 61 | -459 | 62 | 0 |
31 Mar 19 | 61 | -414 | 61 | 0 |
31 Dec 18 | 61 | -386 | 59 | 0 |
30 Sep 18 | 209 | -213 | 65 | 0 |
30 Jun 18 | 203 | -165 | 62 | 0 |
31 Dec 17 | 190 | -17 | 36 | 0 |
Quality Earnings: IDIA is currently unprofitable.
Growing Profit Margin: IDIA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IDIA is unprofitable, but has reduced losses over the past 5 years at a rate of 6.1% per year.
Accelerating Growth: Unable to compare IDIA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IDIA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: IDIA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/08 00:13 |
End of Day Share Price | 2025/01/08 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Idorsia Ltd is covered by 13 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Maria Maldonado | Bank Vontobel AG |
Jean-Philippe Bertschy | Bank Vontobel AG |
Rosie Turner | Barclays |